Together, these observations suggest that COL12A1 is a critical determinant of STAD disease progression and therapy response and exemplifies how comparison of somatic and germline mutations aids interpretation and provides new insights into tumors. This evidence concerns the gene COL12A1 and gastric adenocarcinoma.